Your search for rivaroxaban returned 152 results

Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.

The Food and Drug Administration (FDA) announced that it has approved an update to the prescribing information for Xarelto (rivaroxaban; Janssen).

Results from an ongoing 5-year post-marketing study evaluating the safety of Xarelto (rivaroxaban; Janssen) show that rates and patterns of major bleeding in clinical practice are overall consistent with those seen in Phase 3 clinical trials used to approve the medicine.

Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

High-Alert Medications according to ISMP guidelines

Almost all the various treatment options for acute venous thromboembolism are equally safe and effective, according to a new study.

Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.

Janssen has announced results from its Phase 3b exploratory trial evaluating the efficacy of Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKAs) for treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) in patients undergoing elective cardioversion.

Concomitant use of a nonsteroidal anti-inflammatory drug or aspirin in patients with venous thromboembolism receiving anticoagulant therapy is tied to increased risk of bleeding.